2022 Scientific Programme

2022 Highlights

Through didactic lectures, tandem talks, debates, keynote lectures, and selected abstract presentations, the Scientific Programme examines a range of gastrointestinal malignancies and offers a mix of dynamic education and exchange.

  • Cancer of the Pancreas
    • Hereditary Predisposition to Pancreatic Cancer: Whom and How To Screen and What to Look For?
    • Management of Premalignant Pancreatic Lesions
    • Debate: Molecular Changes in Pancreatic Ductal Adenocarcinoma: NGS in All Patients With PDAC
    • Cases With Panel Discussion: Resectable, Borderline Resectable, and Unresectable Pancreatic Cancer
    • New Treatment Options in Pancreatic Cancer (not on IO)
    • Are We Making Progress in Targeting the Microenvironment and Immune System in PDAC?
    • ESMO Vesalius Talk: How to find Local and International Mentors to Build Your Career in GI Oncology
       
  • Bile Duct Cancer
    • Surgical Resection of Klatskin Tumors and Gall Bladder
    • Cases With Panel Discussion: Locally Advanced Biliary Tract Cancer
    • New Agents in Bile Duct Cancer
    • Cases With Panel Discussion: NGS as the First-line Treatment in All Patients With Advanced Bile Duct Cancer
       
  • ESMO Session: Focus on Young Oncologists (YO) in Collaboration With ESMO Young Oncologist Committee (YOC)
     
  • GI Cancer in Elderly: Challenges and Prospects
     
  • Multidisciplinary Case Discussion on Oligometastatic GI Cancer
     
  • Meet the Experts: Challenging Cases in Advanced HCC
     
  • Esophageal and Gastric Cancers
    • Endoscopic Management of Early Esophageal and Gastric Cancer
    • GE Junction Tumors: Neoadjuvant Chemoradiotherapy (CRT) or Perioperative Chemotherapy (CT)
    • Challenges with PDL Testing in Upper GI Cancer
    • Checkpoint Inhibition in Esophageal Cancer
    • Checkpoint Inhibition in Gastric Cancer
    • New Targets and Agents in Upper GI Cancer (other than HER2)
       
  • Hepatocellular Carcinoma
    • Pathogenesis and Pathology of HCC
    • Diagnostic and Imaging Challenges in HCC
    • Cases With Panel Discussion: Management Strategy in HCC
    • ESMO Lounge Session: Gender Medicine: Time to Address the Topic in GI Tumors
    • How to Integrate and Sequence New Agents in HCC?
    • Challenges and Indications for Locoregional Treatment in HCC
       
  • WCGIC Colloqium 1: Artificial Intelligence in GI Oncology
     
  • WCGIC Colloquium 2: Molecular Marker Platforms
     
  • WCGIC Colloquium 3: NET tumors
     
  • Minisymposium: The Role of Functional Imaging in GI Cancer
     
  • Minisymposium: Special Topics in Young Adults with Cancer
     
  • Meet the Experts: Customized Dosing for Kinase Inhibitors
     
  • Keynote Lectures
    • New Mechanistic Opportunities for Antibodies
    • Targeting the HER-2 Pathway in GI Cancer
       
  • Rectal Cancer
    • MRI: New Data and Learnings in Rectal Cancer
    • Debate: Is TNT standard of Care in Rectal Cancer?
       
  • Flashes
    • Surveillance in Watch & Wait Strategy: How?
    • CPI in MSI-H Locally Advanced Rectal Cancer
    • Cases With Panel Discussion: RAPIDO & PRODIGE strategy
       
  • Cases With Panel Discussion: Oligometastatic Rectal Cancer
     
  • Adjuvant Colon Cancer
    • Is it Time for Personalized Adjuvant Treatment of Colon Cancer? Duration of Adjuvant Treatment
    • Is it Time for Personalized Adjuvant Treatment of Colon Cancer? CtDNA-Based Decisions
    • Immunoscore: A Tool for Escalation/De-escalation of Adjuvant treatment
       
  • ESMO Lounge Session: Disparities in Access to New Drugs: How to Tackle the Reality?
     
  • Immune Mechanisms and Microbiome
    • Understanding Immune Mechanisms and Novel Targets
    • Microbiome and Colorectal Cancer
       
  • Predicting and Managing Rare Toxicities in GI Cancer Patients
     
  • Women for Oncology: The Construction of the Majority Minority
     
  • Surgical Advances in GI Oncology: Transplantation and Robotics
    • Primary Liver Tumors
    • Liver Metastases in Colorectal Cancer
    • Robotic Surgery for Liver Tumors
       
  • Colorectal Cancer: Metastatic Disease
    • Algorithms in First-Line and Second-Line Metastatic Disease
    • Treatment Algorithms After Second-Line Metastatic Disease
    • Checkpoint Inhibitors in MSI-H Colorectal Cancer
    • How to Make MSS Tumors More Sensitive for Immunotherapy
    • BRAF Mutant Tumors: Strategy and New Data
    • Rare Genomic Alterations Including Mutations and Fusions and Discussant
       
  • Rare GI Tumors – NETs, GISTs, and Anal Cancer
    • PRRT in NET
    • GIST:  Molecular Analysis and New Agents
    • Anal Cancer: Role of IOs